Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes

Solvay Pharmaceuticals

Overview

This study is to investigate how well Androgel, when tested against placebo gel, helps to control blood sugar levels in males with type 2 diabetes who have low testosterone (the main male hormone) blood levels and are taking oral diabetic medicines alone or in combination with insulin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Type 2 Diabetes Hypogonadism

Interventions

Androgel (testosterone gel)DRUG

Eligibility

Sex: MALEMin age: 30 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Able to read and write 2. Males 3. Between 30-80 years old 4. Have type 2 diabetes 5. Diagnoses of hypogonadism or low testosterone Exclusion Criteria: 1. On insulin monotherapy 2. Use of testosterone therapy within the last 6 months 3. Male breast cancer 4. History of prostate cancer 5. History of clinically significant sleep apnea

Locations (70)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Site 58

Birmingham, Alabama, United States

Site 67

Calera, Alabama, United States

Site 54

Mobile, Alabama, United States

Site 16

Phoenix, Arizona, United States

Site 35

Anaheim, California, United States

Site 23

Concord, California, United States

Site 55

La Jolla, California, United States

Site 8

Los Gatos, California, United States

Site 12

Mission Viejo, California, United States

Site 1

Torrance, California, United States

...and 60 more locations